肾细胞癌患者血清转化生长因子-β1
Serum transforming growth factor-beta1 in patients with renal cell carcinoma.
作者信息
Wunderlich H, Steiner T, Junker U, Knöfel B, Schlichter A, Schubert J
机构信息
Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany.
出版信息
J Urol. 1997 May;157(5):1602-3.
PURPOSE
A major problem of renal cell carcinoma is the prediction of metastases via tumor prognostic markers. Therefore, much effort has been committed to the development of new prognostic markers.
MATERIALS AND METHODS
The level of transforming growth factor-beta1 was measured by enzyme-linked immunosorbent assay in serum samples collected from patients with renal cell carcinoma before radical nephrectomy.
RESULTS
In serum samples from 21 patients with renal cell carcinoma and 21 healthy controls mean transforming growth factor-beta1 levels were 177 +/- 54.1 versus 65.6 +/- 15.8 ng./ml., respectively. This difference was statistically significant (Mann-Whitney U test p <0.001).
CONCLUSIONS
Increased levels of transforming growth factor-beta1 are common in serum of patients with renal cell carcinoma.
目的
肾细胞癌的一个主要问题是通过肿瘤预后标志物预测转移情况。因此，人们致力于开发新的预后标志物。
材料与方法
采用酶联免疫吸附测定法，检测肾细胞癌患者根治性肾切除术前采集的血清样本中转化生长因子-β1的水平。
结果
21例肾细胞癌患者和21例健康对照者的血清样本中，转化生长因子-β1的平均水平分别为177±54.1 ng/ml和65.6±15.8 ng/ml。这种差异具有统计学意义（曼-惠特尼U检验，p<0.001）。
结论
肾细胞癌患者血清中转化生长因子-β1水平升高很常见。
Zotero 插件